CoChat

BRD4 inhibitors block telomere elongation

Open access

Published version of a preprint

The DOI matches its Crossref record; 74 of the 74 references it cites were found in a registry or an index.

Abstract

Cancer cells maintain telomere length equilibrium to avoid senescence and apoptosis induced by short telomeres, which trigger the DNA damage response. Limiting the potential for telomere maintenance in cancer cells has been long been proposed as a therapeutic target. Using an unbiased shRNA screen targeting known kinases, we identified bromodomain-containing protein 4 (BRD4) as a telomere length regulator. Four independent BRD4 inhibitors blocked telomere elongation, in a dose-dependent manner, in mouse cells overexpressing telomerase. Long-term treatment with BRD4 inhibitors caused telomere shortening in both mouse and human cells, suggesting BRD4 plays a role in telomere maintenance in vivo. Telomerase enzymatic activity was not directly affected by BRD4 inhibition. BRD4 is in clinical trials for a number of cancers, but its effects on telomere maintenance have not been previously investigated.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/nar/gkx561

Cites

74 of 74 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. JQ1 blocks telomere elongation in a dose-dependent manner. Mouse fibroblasts were transduced with SVA lentivirus, encoding for mTERT and mTR and cultured for six days. (A) Southern blot of mouse fibroblast telomeric DNA, at days 2 and 6 post-SVA transduction, grown in the presence of DMSO (lane 2–3), 10 μM KU-55933 (lane 4–5) or 0.1 μM JQ1 (lane 6–7). Lane 1 shows the 2-log ladder marker (NEB) sizes marked in kilobases. (B) Southern blot of mouse fibroblast telomeric DNA, at days 2 and 6 post-SVA transduction, in the presence of DMSO (lane 2–3), 10 μM KU-55933 (lane 4–5) or decreasing concentrations of 33 nM JQ1 (lane 6–7), 11 nM JQ1 (lane 8–9) or 3.3 nM JQ1 (lane 10–11). Lane 1 shows the 2-log ladder marker (NEB) sizes marked are in kilobases.
Figure 1. JQ1 blocks telomere elongation in a dose-dependent manner. Mouse fibroblasts were transduced with SVA lentivirus, encoding for mTERT and mTR and cultured for six days. (A) Southern blot of mouse fibroblast telomeric DNA, at days 2 and 6 post-SVA transduction, grown in the presence of DMSO (lane 2–3), 10 μM KU-55933 (lane 4–5) or 0.1 μM JQ1 (lane 6–7). Lane 1 shows the 2-log ladder marker (NEB) sizes marked in kilobases. (B) Southern blot of mouse fibroblast telomeric DNA, at days 2 and 6 post-SVA transduction, in the presence of DMSO (lane 2–3), 10 μM KU-55933 (lane 4–5) or decreasing concentrations of 33 nM JQ1 (lane 6–7), 11 nM JQ1 (lane 8–9) or 3.3 nM JQ1 (lane 10–11). Lane 1 shows the 2-log ladder marker (NEB) sizes marked are in kilobases.CC BY-NC · PubMed Central
Figure 2. Three additional BRD4 inhibitors block telomere inhibition in a dose-dependent manner. Mouse fibroblasts transduced with SVA lentivirus were treated with four different BRD4 inhibitors: JQ1, IBET151, MS436 OTX015. (A) Southern blot of mouse fibroblast telomeric DNA, at days 2 and 6 post SVA transduction, grown in the presence of DMSO (lane 2–3), 10 μM KU-55933 (lane 4–5), 0.1 μM JQ1 (lane 6–7), 5 μM MS436 (lane 8–9), 0.5 μM OTX015 (lane 10–11) or 1 μM IBET151 (lane 12–13). (B) Dose dependence of IBET151. Southern blot of mouse fibroblast telomeric DNA, at days 2 and 6 post SVA transduction, in the presence of 1 μM (lane 2–3), 0.5 μM (lane 4–5), 0.25 (lane 6–7) or 0.125 μM (lane 8–9) IBET151. (C) Dose dependence of OTX015 and MS436. Southern blot of mouse fibroblast telomeric DNA, at days 2 and 6 post SVA transduction, in the presence of DMSO (lane 2–3), 10 μM KU-55933 (lane 4–5), 250 nM (lane 6–7), 125 nM (lane 8–9) or 62.5 nM OTX015 (lane 10–11), 5 μM (lane 12–13), 2.5 μM (lane 14–15), 1.25 μM (lane 16–17) or 0.625 μM (lane 18–19) MS436. Lane 1 in all panels shows the 2-log ladder marker (NEB), sizes marked are in kilobases. In Panel B, other lanes between the marker and IBET treated lanes were removed.
Figure 2. Three additional BRD4 inhibitors block telomere inhibition in a dose-dependent manner. Mouse fibroblasts transduced with SVA lentivirus were treated with four different BRD4 inhibitors: JQ1, IBET151, MS436 OTX015. (A) Southern blot of mouse fibroblast telomeric DNA, at days 2 and 6 post SVA transduction, grown in the presence of DMSO (lane 2–3), 10 μM KU-55933 (lane 4–5), 0.1 μM JQ1 (lane 6–7), 5 μM MS436 (lane 8–9), 0.5 μM OTX015 (lane 10–11) or 1 μM IBET151 (lane 12–13). (B) Dose dependence of IBET151. Southern blot of mouse fibroblast telomeric DNA, at days 2 and 6 post SVA transduction, in the presence of 1 μM (lane 2–3), 0.5 μM (lane 4–5), 0.25 (lane 6–7) or 0.125 μM (lane 8–9) IBET151. (C) Dose dependence of OTX015 and MS436. Southern blot of mouse fibroblast telomeric DNA, at days 2 and 6 post SVA transduction, in the presence of DMSO (lane 2–3), 10 μM KU-55933 (lane 4–5), 250 nM (lane 6–7), 125 nM (lane 8–9) or 62.5 nM OTX015 (lane 10–11), 5 μM (lane 12–13), 2.5 μM (lane 14–15), 1.25 μM (lane 16–17) or 0.625 μM (lane 18–19) MS436. Lane 1 in all panels shows the 2-log ladder marker (NEB), sizes marked are in kilobases. In Panel B, other lanes between the marker and IBET treated lanes were removed.CC BY-NC · PubMed Central
Figure 3. BRD4 inhibition does not affect telomerase enzyme activity. (A) Direct telomerase assay using whole cell lysates of 293TRex cells overexpressing hTR, TERT, POT1 and TPP1, which were treated with DMSO (lane 1), 0.5 μM JQ1 (lane 2), 2.5 μM OTX015 (lane 3), 25 μM MS436 (lane 4) or 5 μM IBET151 (lane 5). Lanes 6–10 show extracts pretreated with RNase A to show activity due to RNase sensitive telomerase enzyme. (B) Quantification of telomerase processivity and (C) Quantification of telomerase catalytic activity as described in ‘Materials and Methods’ section. Values in (B) and (C) are averages of two technical replicates. Error bars in (C) represent the standard deviation.
Figure 3. BRD4 inhibition does not affect telomerase enzyme activity. (A) Direct telomerase assay using whole cell lysates of 293TRex cells overexpressing hTR, TERT, POT1 and TPP1, which were treated with DMSO (lane 1), 0.5 μM JQ1 (lane 2), 2.5 μM OTX015 (lane 3), 25 μM MS436 (lane 4) or 5 μM IBET151 (lane 5). Lanes 6–10 show extracts pretreated with RNase A to show activity due to RNase sensitive telomerase enzyme. (B) Quantification of telomerase processivity and (C) Quantification of telomerase catalytic activity as described in ‘Materials and Methods’ section. Values in (B) and (C) are averages of two technical replicates. Error bars in (C) represent the standard deviation.CC BY-NC · PubMed Central
Figure 4. BRD4 inhibition causes telomere shortening in human and mouse cells in culture. (A) Southern blot of telomeric DNA from HeLa cells treated with DMSO (lane 2–5), or 2.5 μM OTX015 (lane 6–9) for 6 weeks, with samples taken at 2, 4 and 6 weeks of treatment. (B) Southern blot of telomeric DNA from mouse fibroblast cells, which were treated with DMSO (lane 2–5), or 0.5 μM OTX015 (lane 6–9) for 6 weeks, with samples taken at 2, 4 and 6 weeks of treatment.
Figure 4. BRD4 inhibition causes telomere shortening in human and mouse cells in culture. (A) Southern blot of telomeric DNA from HeLa cells treated with DMSO (lane 2–5), or 2.5 μM OTX015 (lane 6–9) for 6 weeks, with samples taken at 2, 4 and 6 weeks of treatment. (B) Southern blot of telomeric DNA from mouse fibroblast cells, which were treated with DMSO (lane 2–5), or 0.5 μM OTX015 (lane 6–9) for 6 weeks, with samples taken at 2, 4 and 6 weeks of treatment.CC BY-NC · PubMed Central
Figure 5. BRD4 inhibition increases chromosome fusions. Mouse fibroblast cells shown in Figure 4B from 6 weeks of growth were further grown in OTX015 or DMSO and metaphases were processed for telomere FISH. (A) There was a significant increase in fusions per metaphase from 2.8 to 4.5 (P = 0.003 t-test) and a significant increase in signal free ends from 0.4 to 1.2 (P = 0.016 t-test). (B) Representative Metaphase showing chromosome fusions. Arrows indicate chromosome p-arm fusions and asterisk indicates a q-arm fusion.
Figure 5. BRD4 inhibition increases chromosome fusions. Mouse fibroblast cells shown in Figure 4B from 6 weeks of growth were further grown in OTX015 or DMSO and metaphases were processed for telomere FISH. (A) There was a significant increase in fusions per metaphase from 2.8 to 4.5 (P = 0.003 t-test) and a significant increase in signal free ends from 0.4 to 1.2 (P = 0.016 t-test). (B) Representative Metaphase showing chromosome fusions. Arrows indicate chromosome p-arm fusions and asterisk indicates a q-arm fusion.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 74 references

Cited by

See all 48

Metadata

Authors
Wang, S., Pike, A. M., Lee, S. S., Strong, M. A., Connelly, C. J., & Greider, C. W.
Affiliations
Johns Hopkins University (US)
Corresponding author
Greider, Carol W.
Venue
Nucleic Acids Research
Published
2017-06-30
Volume
45
Issue
14
Pages
8403-8410
ISSN
  • 0305-1048 (ISSN-L)
  • 1362-4962
OpenAlex
W2949192443
Cited by
45
References
74
Citations by year
2026: 6 · 2025: 4 · 2024: 1 · 2023: 6 · 2022: 3 · 2021: 4 · 2020: 8 · 2019: 9 · 2018: 2 · 2017: 1
FWCI
4.05
Type
journal article
Language
en
Open access
Locations
  • Nucleic Acids Research (publishedVersion, cc-by-nc)
  • bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
  • Johns Hopkins University
  • National Institutes of Health
  • University of California, Riverside
  • National Cancer Institute (R01CA160300)
  • National Institute of General Medical Sciences (T32GM008752)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA and Nucleic Acid Chemistry
Keywords
BRD4, bromodomain proteins, telomere maintenance, telomere elongation, telomerase, telomere shortening, cancer therapy, shRNA screen, kinases, DNA damage response, cellular senescence
MeSH terms
Acetanilides, Bromodomain Containing Proteins, Animals, Azepines, Cell Line, Dose-Response Relationship, Drug, Fibroblasts, HeLa Cells, Heterocyclic Compounds, 3-Ring, Heterocyclic Compounds, 4 or More Rings, Humans, Morpholines, Nuclear Proteins, Pyrones, Transcription Factors, Triazoles, Blotting, Southern, Gene Expression, Telomere, In Situ Hybridization, Fluorescence, Cell Cycle Proteins, Telomerase, RNA Interference, Mice, Telomere Homeostasis, Telomere Shortening

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: BRD4 inhibitors block telomere elongation. https://app.cochat.ai/papers/10.1093/nar/gkx561
The paper
Wang, S., Pike, A. M., Lee, S. S., Strong, M. A., Connelly, C. J., & Greider, C. W. (2017). BRD4 inhibitors block telomere elongation. Nucleic Acids Research. https://doi.org/10.1093/nar/gkx561

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.